Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 308Carcinoma, Non-Small-Cell Lung 241Prostatic Neoplasms 198Neoplasms 191Lung Neoplasms 149Multiple Myeloma 144Neoplasm Metastasis 110Colorectal Neoplasms 105Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 81Pancreatic Neoplasms 77Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 70Carcinoma, Renal Cell 68Lymphoma, Non-Hodgkin 64Squamous Cell Carcinoma of Head and Neck 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 59Urinary Bladder Neoplasms 58Recurrence 56Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Glioblastoma 53Endometrial Neoplasms 52Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Sarcoma 46Precursor Cell Lymphoblastic Leukemia-Lymphoma 46

Interventions

Specimen Handling 1Biopsy 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Serous Adenocarcinoma × 90 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡